250 related articles for article (PubMed ID: 32407173)
1. Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma.
Zhang PF; Xie D; Li Q
Future Oncol; 2020 Jun; 16(17):1189-1198. PubMed ID: 32407173
[No Abstract] [Full Text] [Related]
2. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
3. [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].
Reich M; Coutzac C
Bull Cancer; 2021 Mar; 108(3):228-229. PubMed ID: 33531154
[No Abstract] [Full Text] [Related]
4. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.
Kato K; Doki Y; Ura T; Hamamoto Y; Kojima T; Tsushima T; Hironaka S; Hara H; Kudo T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Kitagawa Y
Cancer Sci; 2020 May; 111(5):1676-1684. PubMed ID: 32160365
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D
Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China.
Lin YT; Liu TX; Chen J; Wang C; Chen Y
Front Public Health; 2022; 10():923619. PubMed ID: 35844891
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
Sarfaty M; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Apr; 73(4):628-634. PubMed ID: 28807351
[TBL] [Abstract][Full Text] [Related]
9. A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.
Tang Y; Ou Z; Yao Z; Qiao G
Medicine (Baltimore); 2019 Oct; 98(40):e17164. PubMed ID: 31577707
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
Lee J; Kim B; Jung HA; La Choi Y; Sun JM
Cancer Immunol Immunother; 2021 May; 70(5):1203-1211. PubMed ID: 33123755
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
[No Abstract] [Full Text] [Related]
12. Emerging data on nivolumab for esophageal squamous cell carcinoma.
Hirose T; Yamamoto S; Kato K
Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update.
Shah MA; Hofstetter WL; Kennedy EB;
J Clin Oncol; 2021 Oct; 39(28):3182-3184. PubMed ID: 34406872
[No Abstract] [Full Text] [Related]
15. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
Gibson EJ; Begum N; Koblbauer I; Dranitsaris G; Liew D; McEwan P; Yuan Y; Juarez-Garcia A; Tyas D; Pritchard C
J Med Econ; 2019 Jun; 22(6):531-544. PubMed ID: 30638416
[No Abstract] [Full Text] [Related]
16. Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma: A Cost-Utility Analysis.
Raphael J; Sun Z; Bjarnason GA; Helou J; Sander B; Naimark DM
Am J Clin Oncol; 2018 Dec; 41(12):1235-1242. PubMed ID: 29727313
[TBL] [Abstract][Full Text] [Related]
17. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
18. Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial.
Marguet S; Adenis A; Delaine-Clisant S; Penel N; Bonastre J
Value Health; 2021 May; 24(5):676-682. PubMed ID: 33933236
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience.
Kao MW; Kuo YH; Hsieh KC; Lee CT; Wu SC; Yang WC
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108474
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Tringale KR; Carroll KT; Zakeri K; Sacco AG; Barnachea L; Murphy JD
J Natl Cancer Inst; 2018 May; 110(5):479-485. PubMed ID: 29126314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
